The expanded reimbursement access aims to make the FDA-cleared device more affordable for patients with conditions linked to hypoxia.
Key takeaways:
Eligible patients may now access OxiWear’s continuous oxygen measuring device through Medicare and participating insurance providers. This expansion helps increase access for individuals living with chronic respiratory, cardiovascular, and other conditions with associated hypoxia.
OxiWear is a US Food and Drug Administration-cleared wearable device designed to provide continuous blood oxygen measurement and real-time low-oxygen alerts during both motion and rest. The device enables patients and healthcare providers to identify oxygen desaturation that may otherwise go undetected
“I started OxiWear as a personal mission to help people like me live life to the fullest despite the challenges of living with conditions that put us at risk of low oxygen levels,” says Shavini Fernando, founder and CEO of OxiWear, in a release. “Since receiving FDA clearance, one of our biggest priorities has been solving the reimbursement challenge and ensuring patients can access this technology without creating an additional financial burden. I’m incredibly proud that we’ve been able to work through those barriers and make OxiWear available through insurance coverage. Now, more patients can access the continuous oxygen data they need with greater affordability and peace of mind.”
Cleared for both clinical and at-home settings, OxiWear demonstrated high performance across diverse skin tones during the FDA review process. This addresses longstanding concerns regarding disparities in pulse oximetry accuracy and ensures more equitable oxygen measurement for all patients.
By expanding reimbursement access, OxiWear aims to improve patient outcomes, reduce avoidable hospitalizations, lower healthcare costs, and provide greater peace of mind for patients, caregivers, and healthcare providers.
| # | Наименование новости | Тональность | Информативность | Дата публикации |
|---|---|---|---|---|
| 1 | Next-Gen Reusable HST Boasts Immediate Access to Results | 0 | 5 | 21-06-2026 |
| 2 | Huxley Medical Expands SANSA Diagnostic Platform with Point-of-Care Enrollment Workflow | 0 | 5 | 12-06-2026 |
| 3 | SovaSage Releases AI-Powered Tool for CPAP Patient Management | 0 | 7 | 13-07-2026 |
| 4 | Bryggs Medical Launches ULTepap 2 with Adjustable Pressure Settings | 0 | 5 | 06-07-2026 |
| 5 | Apnimed Appoints New CEO as Investigational OSA Therapy Nears FDA Decision | 0 | 5 | 22-06-2026 |
| 6 | Ognomy Sleep Secures $20M Series A to Expand AI-Enabled Sleep Apnea Care | 5 | 7 | 01-07-2026 |
| 7 | The Wearables Debate Is Evolving | 0 | 7 | 01-07-2026 |
| 8 | Nox Health Appoints New CEO | 0 | 5 | 29-06-2026 |
| 9 | AI Platform Adds Sleep Wellness Sensor to Senior Living Kit | 0 | 5 | 30-06-2026 |
| 10 | ProSomnus, MonitAir Partner to Integrate OSA Remote Monitoring | 0 | 5 | 16-06-2026 |